West Pharmaceutical Services shares rise after reporting a Q4 earnings beat and full-year 2025 results, and issuing initial FY2026 profit guidance above Wall Street estimates and Q1 2026 guidance, incorporating the planned sale of its SmartDose 3.5 mL on-body delivery system to AbbVie.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.